California Biotech Insights

Kevin Green serves as Chief Operating Officer at Elsie Biotechnologies, previously acting as Chief Financial Officer and Chief Business Officer. Kevin is an experienced healthcare executive with a broad finance and operations background in life sciences, medical devices and biotechnology. He is an experienced fundraiser and strategic thinker, preparing companies for private financing and IPOs, and has extensive business development expertise with deep networks in pharma, biotech, and banking. Prior to Elsie, Kevin served as Chief Financial Officer & Senior Vice President, Corporate Development at Bioniz Therapeutics. He also served as Vice President, Business & Corporate Development at Aivita Biomedical after serving as Senior Director of Business Development at Allergan for 10 years. Kevin earned his MBA from University of California, Irvine. 

Irit Rappley serves as Chief Scientific Officer at Teal Omics. She is a scientific and strategic leader with demonstrated success developing and implementing organizational and drug discovery portfolio strategies.​ ​Throughout her previous leadership roles, Irit has developed vast experience with all stages of drug discovery, from screening and target validation to translational biomarkers and first in human trials, with deep expertise in neurodegenerative diseases and protein homeostasis across multiple modalities. Prior to joining Teal, Irit served as VP Neuroscience & Translational Research at Recursion, and previously she helped build the Neuroscience group at Celgene/BMS from the ground up. Irit earned her PhD in Neuroscience from Harvard University, and Bachelor’s in Brain and Cognitive Sciences from MIT. 

Dr. Raphael Ribeiro-Pinaud is the Founder, CEO and Chairman of Antharis Therapeutics, where he has launched and grown the company to significant success, spearheaded M&A transactions with Cassyni Biopharma and Galileo Biotech, and expanded Antharis’ asset portfolio and multinational presence. His expertise in the biotech/biopharma sector resides at the intersection of science, finance,business management and regulatory affairs. Before Antharis, he founded GB, a pioneering GMP-certified diagnostics company in Latin America, and served as a partner at Leste Global Investments, managing global biotech investments. Dr. Ribeiro-Pinaud has also held roles as an academic scientist and advisor to governmental health agencies. He holds a Ph.D. in Neuroscience from OHSU, completed postdoctoral work at Duke in Bioengineering/Proteomics, earned an MBA in Economics and Business Management from FGV Business School in Brazil, and graduated from Harvard’s Finance Leadership program.

Dr. Jermaine Ross co-founded Alleo Labs in 2023 and serves as CEO and President. He brings years of industry experience in drug discovery and machine learning from his previous executive role as Vice President and Head of Neuroscience at Immuneering Corporation (NASDAQ: IMRX), which he co-led to an IPO in 2021. Prior to that Dr. Ross trained as a neuroscientist and computational biologist at the National Institutes of Health for over 10 years. He received his bachelor’s degree from the University of Michigan in Molecular, Cellular and Developmental Biology, and holds a doctoral degree in Neuroscience from Brown University. He is also a board member of the Alzheimer’s Association in New York City, and is a William H. Gates Sr. Fellow from the Alzheimer’s Disease Data Initiative.